# LASER301: HCP commentary report

> 88 verified statements (47 from clinicians verified by NPI or staff page) from 18 commentary sources · 10 findings · updated Oct 31, 2026

## Report

- Trial: A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT ID: NCT04248829
- Registry: https://clinicaltrials.gov/study/NCT04248829
- Sponsor: Yuhan Corporation
- Phase: Phase 3
- Status: Completed
- Drugs tested: lazertinib
- Indication: first-line EGFR-mutated locally advanced or metastatic NSCLC
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: c6178e9a2c231dea479a9eff9459154cf92a35d9b543fb6b81bbd1b73ac68ca0

## Counts

- HCP commentary sources screened: 48
- Sources cited by verified statements: 22
- Verified statements: 88
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 47
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 20
- Voices cited: 20
- Cited voices identity-verified: 15
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

LASER301 asks whether first-line lazertinib delays progression compared with gefitinib in previously untreated patients with advanced non-small-cell lung cancer harboring sensitizing EGFR mutations. Commentary comes from X and LinkedIn posts and podcasts, including a medical oncologist. The discussion turns on gefitinib’s contested relevance as a comparator, whether lazertinib offers an alternative to osimertinib rather than an advance, and how toxicity makes selection between the drugs conditional.

## Open Medical Affairs question

What evidence would justify choosing an additional monotherapy option or intensifying treatment for a particular patient, after accounting for subtype uncertainty, CNS risk, tolerability, access and the subsequent treatment pathway?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A positive trial against gefitinib still leaves a contested contemporary comparator
- F2. An osimertinib-like alternative is a recurrent interpretation, not demonstrated superiority or equivalence
- F3. A subtype-based L858R preference is expressed strongly, but its explanation remains hypothetical
- F4. Different toxicity profiles motivate conditional choice, not a blanket safety ranking
- F5. CNS activity elicits enthusiasm without eliminating surveillance or evidentiary limits
- F6. Earlier access, affordability and reassurance contribute to perceived clinical value
- F7. First-line intensification is framed as a benefit–burden and shared-decision question
- F8. Overall survival and the pattern of progression may matter beyond the PFS interval
- F9. An upfront choice may alter resistance and consume a preferred later-line option
- F10. Testing supports immunotherapy deferral, with an explicit urgent-treatment exception

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 8 | 8 | 6 | 5 | recorded | 2 |
| F2 | 14 | 13 | 6 | 8 | recorded | 2 |
| F3 | 6 | 6 | 3 | 5 | recorded | 2 |
| F4 | 8 | 7 | 4 | 4 | recorded | 3 |
| F5 | 9 | 8 | 6 | 5 | recorded | 3 |
| F6 | 8 | 5 | 4 | 4 | recorded | 3 |
| F7 | 8 | 5 | 3 | 3 | recorded | 3 |
| F8 | 4 | 4 | 3 | 2 | none recorded | 2 |
| F9 | 4 | 3 | 1 | 1 | none recorded | 3 |
| F10 | 5 | 2 | 1 | 1 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 0 | 0 | 2 | 0 | 9 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F2 | 5 | 3 | 0 | 6 | 0 | 15 | 1 | 4 posts and articles, 2 podcasts and video | yes |
| F3 | 2 | 1 | 0 | 3 | 0 | 6 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F4 | 4 | 0 | 0 | 4 | 0 | 8 | 1 | 3 posts and articles, 1 podcast or video | yes |
| F5 | 6 | 0 | 0 | 0 | 3 | 10 | 0 | 4 posts and articles, 1 podcast or video, 1 publication | yes |
| F6 | 3 | 0 | 1 | 3 | 1 | 8 | 0 | 3 posts and articles, 1 podcast or video | yes |
| F7 | 5 | 0 | 1 | 2 | 0 | 8 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F8 | 3 | 0 | 0 | 0 | 1 | 5 | 0 | 1 post or article, 1 podcast or video, 1 publication | yes |
| F9 | 2 | 1 | 1 | 0 | 0 | 4 | 1 | 1 podcast or video | yes |
| F10 | 3 | 0 | 1 | 0 | 1 | 5 | 0 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment: F1 (2 shared claims), F2 (1 shared claims), F6 (1 shared claims)
- Secondary endpoints: F5 (3 shared claims), F8 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (2 shared claims), F3 (4 shared claims), F6 (2 shared claims), F7 (2 shared claims)
- The comparison: F1 (5 shared claims), F2 (6 shared claims), F3 (2 shared claims), F4 (2 shared claims), F6 (2 shared claims)
- Safety and tolerability: F2 (2 shared claims), F4 (8 shared claims), F7 (2 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (1 shared claims), F6 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. An osimertinib-like alternative is a recurrent interpretation, not demonstrated superiority or equivalence

An X thread asked whether lazertinib improves clinical outcomes relative to osimertinib.

Source: X thread, 2022-12-03.

### F3. A subtype-based L858R preference is expressed strongly, but its explanation remains hypothetical

An X exchange asked how adding chemotherapy to osimertinib might affect its comparison with lazertinib in L858R disease.

Source: X thread, 2026-01-16.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 88 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 22 | Counts free |
| Speaker attribution for cited voices | 20 | Paid |

## Trial aspects

13 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment | discussed | 10 | 6 |
| Secondary endpoints | discussed | 5 | 4 |
| Population and setting | discussed | 8 | 4 |
| The comparison | discussed | 14 | 5 |
| Safety and tolerability | discussed | 10 | 4 |
| Design and conduct | discussed | 4 | 4 |
| Direct comparison with osimertinib and contribution of components | discussed | 20 | 5 |
| CNS activity, monitoring and the clinical pattern of progression | discussed | 9 | 6 |
| L858R-specific choice and a proposed biologic edge | discussed | 3 | 1 |
| Access, price, earlier-line opportunity and patient reassurance | discussed | 9 | 3 |
| Monotherapy versus first-line intensification: benefit, burden and shared choice | discussed | 12 | 4 |
| Resistance, sequencing and preservation of later-line options | discussed | 5 | 2 |
| Rapid testing, immunotherapy deferral and urgent chemotherapy | discussed | 5 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 44 | 15 |
| Podcasts | 2 | 2 |
| LinkedIn posts | 1 | 1 |
| Bluesky threads | 1 | 0 |
| Publications (primary source, cited for context) | not screened | 2 |
| Registry (primary source, cited for context) | not screened | 2 |

- Screened window: 2020-01-30 to 2026-09-08
- Cited window: 2020-09-21 to 2026-01-16
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Registry: NCT04248829 (https://clinicaltrials.gov/study/NCT04248829)
- Study IDs: YH25448-301
- Sponsor: Yuhan Corporation
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Completed
- Enrollment: 393 (actual)
- Start: 2020-02-13 (actual)
- Primary completion: 2022-07-29 (actual)
- Primary endpoint: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment (At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.)
- Intervention: Lazertinib 240 mg/160 mg (drug)
- Intervention: Gefitinib 250 mg (drug)
- Intervention: Lazertinib-matching placebo 240 mg/160 mg (drug)
- Intervention: Gefitinib-matching placebo 250 mg (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on immature overall survival evidence when weighing first-line treatment options for advanced EGFR-mutated lung cancer.
- Not yet captured in this edition: a view on first-line combination treatment and expectations for immature overall survival evidence.
- Not yet captured in this edition: a question about combining amivantamab with osimertinib rather than lazertinib in first-line EGFR-mutated advanced lung cancer.
- Not yet captured in this edition: a view on tentative cross-trial efficacy comparisons as a rationale for first-line treatment enthusiasm.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 119 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The report describes the sources reviewed for this edition, not all HCPs or all public discussion; source totals and repeated posts cannot be interpreted as independent-clinician counts.
- Some passages have not been fully assessed for clinical views, including portions of the a podcast episode published on 3 August 2024. Coverage of that episode does not support a complete account of its resistance rationale, administration-route preferences, early efficacy–toxicity appraisal or tentative cross-trial calculations. Discussion that omits the trial name or uses different spellings may also be missing, so an unmentioned issue is not evidence of no concern.
- Several podcast passages lack an identifiable speaker. Their views remain attached to the episode and cannot be assigned from its title or guest list.
- Some named authors have no established clinical role in these sources; other professional descriptions come only from the source itself. Named or verified identity does not increase the truth or representativeness of a view.
- Cross-trial comparisons, clinical impressions, hypotheses and questions are not head-to-head findings. MARIPOSA, FLAURA2 and MARIPOSA-2 observations remain attached to those studies and settings.
- LASER301 CNS findings apply to the eligible asymptomatic or stable CNS population. The intracranial response-rate difference was numerical and not statistically significant, despite enthusiastic response-rate commentary.
- The LASER301 primary publication's OS analysis was immature and not statistically significant. OS statements about MARIPOSA cannot establish a LASER301 OS benefit.
- Reported approvals, reimbursement conditions, availability and prices are dated source accounts. Exact current country-specific indications and access are not established here.
- Publication and post dates do not establish session dates, a change of mind, or disagreement between statements made in different settings.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (88 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (15 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/laser301-nct04248829
- Agents: POST https://www.erudio.com/api/orders with {"report": "laser301-nct04248829", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=laser301-04248829

## Cite

Erudio Health. LASER301 (NCT04248829): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/laser301-nct04248829

## Machine access

- JSON: https://www.erudio.com/reports/laser301-nct04248829.json
- Markdown: https://www.erudio.com/reports/laser301-nct04248829.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "laser301-04248829"}`